Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta, Daniel Lopes de Menezes, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-137606

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Hartmut Döhner, MD, Paresh Vyas, MD PhD, John F. Seymour, MD, Valeria Santini, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Haifa Kathrin Al-Ali, MD, Teresa Bernal del Castillo, MD PhD, John Morrill, MS, Stephen Songer, PharmD, Jerry Weaver, PhD, Barry S. Skikne, MD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 1638.

https://doi.org/10.1182/blood.V128.22.1638.1638

Published: 2016

Journal Articles

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Valeria Santini, MD, Pierre Fenaux, MD PhD, Aristoteles Giagounidis, Uwe Platzbecker, MD, Alan F List, MD, Jianhua Zhong, PhD, Chengqing Wu, PhD, Konstantinos Mavrommatis, C.L. Beach, PharmD, Albert Hoenekopp, MD, Kyle J. MacBeth, PhD

Blood (2016) 128 (22): 225.

https://doi.org/10.1182/blood.V128.22.225.225

Published: 2016

Journal Articles

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Lin Tang, PhD, Anna Dolnik, PhD, Kyle J. MacBeth, PhD, Hervé Dombret, Prof., John F. Seymour, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, C.L. Beach, PharmD, Hartmut Döhner, MD, Lars Bullinger, MD

Blood (2016) 128 (22): 2859.

https://doi.org/10.1182/blood.V128.22.2859.2859

Published: 2016

Journal Articles

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

John F. Seymour, MD, Rena Buckstein, MD, Valeria Santini, MD, Hartmut Döhner, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Ching-Yuan Kuo, MD, Dina Ben-Yehuda, MD, Joan Bargay, MD, Stephen Songer, PharmD, Jerry Weaver, PhD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 2818.

https://doi.org/10.1182/blood.V128.22.2818.2818

Published: 2016

Journal Articles

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

John F. Seymour, MBBS, PhD, Lewis R. Silverman, MD, Hartmut Döhner, Prof. MD, Pierre Fenaux, MD PhD, Ghulam J. Mufti, MD PhD, Valeria Santini, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, Lela M. Lucy, PhD, Stephen Songer, PharmD, Donna Dougherty, BSN, Randy Hinkle, RPh, MBA, Dominique Gambini, MD, C.L. Beach, PharmD, Hervé Dombret

Blood (2015) 126 (23): 3754.

https://doi.org/10.1182/blood.V126.23.3754.3754

Published: 2015

Journal Articles

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Dalia Mahmoud, MBA, Stacie Hudgens, MS, Fiona Taylor, MBiochem, Farrah Pompilus, MA, Steve Hwang, BA, C.L. Beach, PharmD

Blood (2012) 120 (21): 4705.

https://doi.org/10.1182/blood.V120.21.4705.4705

Published: 2012

Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD

Blood (2012) 120 (21): 3808.

https://doi.org/10.1182/blood.V120.21.3808.3808

Published: 2012

Journal Articles

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Benjamin Esterni, Ph.D., Raphael Itzykson, Sylvain Thepot, C.L. Beach, PharmD, Pierre Fenaux, MD, PhD, Norbert Vey, MD

Blood (2010) 116 (21): 443.

https://doi.org/10.1182/blood.V116.21.443.443

Published: 2010

Journal Articles

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Thomas Prebet, M.D., Ph.D., Zhuoxin Sun, PhD, Rhett Ketterling, Gary Hicks, Ph.D., C.L. Beach, PharmD, Peter L. Greenberg, MD, Elisabeth Paietta, PhD, Magdalena Czader, M.D., Ph.D., Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD, Steven D. Gore, M.D.

Blood (2010) 116 (21): 4013.

https://doi.org/10.1182/blood.V116.21.4013.4013

Published: 2010

Journal Articles

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Pierre Fenaux, MD, G.J. Mufti, MD, V. Santini, MD, C. Finelli, MD, A. Giagounidis, MD, R. Schoch, MD, A.F. List, MD, S.D. Gore, MD, J.F. Seymour, MD, E. Hellstrom-Lindberg, MD, J.M. Bennett, MD, J.C. Byrd, MD, J.T. Backstrom, MD, L.S. Zimmerman, BSN, D.R. McKenzie, MS, C.L. Beach, PharmD, L.R. Silverman, MD

Blood (2007) 110 (11): 817.

https://doi.org/10.1182/blood.V110.11.817.817

Published: 2007

Journal Articles

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, Indra Fernando, Jay Backstrom, MD, C.L. Beach, PharmD

Blood (2007) 110 (11): 819.

https://doi.org/10.1182/blood.V110.11.819.819

Published: 2007

Journal Articles

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

Roger M. Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Heidi McIntyre, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH

Blood (2006) 108 (11): 2662.

https://doi.org/10.1182/blood.V108.11.2662.2662

Published: 2006

Journal Articles

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Lewis R. Silverman, MD, David R. McKenzie, MS, Bercedis L. Peterson, PhD, Carlos M. De Castro, MD, John Ellerton, MD, Kathryn N. Knapp, MS, C.L. Beach, PharmD, Richard A. Larson, MD, The Cancer Leukemia Group B (CALGB).

Blood (2005) 106 (11): 2526.

https://doi.org/10.1182/blood.V106.11.2526.2526

Published: 2005

Journal Articles

Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

Roger Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Linda Lintz, BA, C.L. Beach, PharmD, Jay T. Backstrom, MD, MPH

Blood (2005) 106 (11): 2517.

https://doi.org/10.1182/blood.V106.11.2517.2517

Published: 2005

NARROW

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study

The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)

Quality of Life and Productivity Impact of Myelodysplastic Syndromes (MDS): The Patient Perspective

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure

A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).

Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes.

Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.

Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only